Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5443_Библиотеки_им_академика_М_И_Перельмана
.pdf
mal formulations were predicted and modeled with the help of ANN such as INform 3.1.
This method demonstrated how AI-guided QbD may be used to create efficient medica-
tion delivery systems for cervical and lung cancer. This approach showcased the poten-
tial of AI-guided QbD in designing effective drug delivery systems for lung and cervical
cancer treatment [58]. Another study by Maharajan and colleagues examined the rela-
tionship between QbD and AI in terms of optimizing the formulation of mRNA-LNP vac-
cines using AI meth odologies in conjunction with a Definitive Screening Design.
Variations were made in lipid types, ratios, and flow rates, and the effects on EE, ZP,
PdI, and PS were evaluated. Predictive accuracy was the goal of the study using ML al-
gorithms such as XGBoost, SVM, etc. In comparison to other ML models, the combinato-
rial ANN-DoE model performed exceptionally well, accurately predicting the following:
PS: 61.36 ± 11.80 nm, PDI: 0.15 ± 0.09, ZP: 0.13 ± 1.17 mV, and EE: 88.74 ± 7.58%. This
method was effectively optimized using AI and QbD principles [59]. Hydrophobic phar-
maceuticals demonstrate insufficient solubility in water and first-pass metabolism fre-
quently makes it difficult for them to be effectively delivered orally. To address these
issues, poor water-soluble drugs have been encapsulated and their absorption into tis-
sues has been improved through the development of sophisticated delivery methods
for such solid lipid NPs (SLNs) and NLCs. Inevitably, due to their restriction to a rela-
tively small design area, typical design techniques for these multifaceted formulations
can pose sophisticated complications. At this point, researchers provide a data-driven
method which utilizes experimental automation and ML to create SLNs/NLCs more
quickly by encasing a model hydrophobic medicine, cannabidiol. Employing downsized
experimentation technology to increase throughput and reduce the amount of medicine
and ingredients needed, a tiny subset of formulations – roughly 10% of all formulations
in the design space – were created internally. The characteristics of all SLNs/NLCs in-
side this design space – that is, 1,215 formulae – were then predicted by ML models that
were constructed on the data produced by these formulations. Additionally, formula-
tions identified by this method as among the best responders were found to consider-
ably increase the medication’s solubility by up to 3,000-fold and effectively prevent the
drug from degrading. Furthermore, as compared to the free drug and an over-the-
counter form, these developed best responder’s formulae greatly increased the drug’s
bioavailability when taken orally. Moreover, this bioavailability was consistent with a
formulation whose composition was similar to that of the FDA-approved Epidiolex®
[60]. Another cohort utilized ANN for the development of poly(3-hydroxybutyrate-co-3-
hydroxyvalerate)-based biodegradable NPs (PHBV-NPs) of an immunosuppressive drug,
that is, Fingolimod. A computerized learning technique called ANN mimicked the neu-
rological effects of the human brain to create the most accurate model possible. The
input factors were the concentration of PHBV, polyvinyl alcohol, and amount of drug
while the outputs were PS of NPs, PdI, EE, and drug loading. To determine the optimal
model for in vitro release in terms of reliability and understanding, a multilayer per-
ceptron with distinct training algorithms has been investigated. The ANN models had
been developed using three different training model compositions: gradient descent,
8 QbD and artificial intelligence in nanoparticulate drug delivery systems 173
https://t.me/med1917
Bayesian regularization, and Levenberg–Marquardt (LM). Out of these three models,
LM was the best performer, then Bayesian regularization, followed by gradient descent.
Additionally, the LM training algorithm with 15 concealed layers and 20 neurons pro-
duced the best formulation. Also, the optimization procedure was created by reducing
the error (about 0.0341) between the training algorithm’s anticipated and observed out-
comes [61]. Utilizing ML algorithms, that is, neural networks, and clustering with princi-
pal component analysis along with cationic-charged glycerol-based lipids, viz., GLY1
and GLY2, researchers developed NLC for the treatment of glioblastoma. The only dis-
tinguishing feature between these two molecules – which have a glycerol backbone and
two alkylated chains – is their polar head. They worked well to reverse the nanosys-
tem’s ZP to the positive range. Their structural similarities were revealed by applying
supervised and unsupervised ML approaches. GLY1 performed better in terms of boost-
ing cytotoxicity and ZP although reducing PS while sharing a similar backbone with the
other compounds [62].
8.5 Challenges and future aspects
The formulation and process optimization for NDDS is intricate. Key factors such as PS,
shape, surface charge, and composition play substantial roles in influencing system per-
formance. Therefore, designing a robust formulation and optimizing the process to
achieve the desired product quality can be challenging. QbD principles demand a thor-
ough understanding of the CQAs and CPPs that impact the product [63]. In the case of
NDDS, the identification of critical factors and their intricate relationship with CQAs
can prove to be challenging. Additionally, the design space for these systems is often
intricate, adding complexity to the task of developing a robust design [64]. Moreover,
the variability introduced by factors such as raw materials, manufacturing processes,
and environmental conditions complicates the establishment of consistent quality
throughout the NP development process [65]. Addressing this variability necessitates ro-
bust risk assessment methodologies and proactive approaches to address potential is-
sues during the design phase. Balancing the need for flexibility with the requirement
for a standardized approach poses an ongoing challenge, as excessive flexibility may
compromise reproducibility, while too much standardization may stifle innovation [66].
Furthermore, integrating QbD principles into the entire lifecycle of NDDS poses a con-
siderable challenge. The continuous monitoring and adaptation required to uphold
quality objectives from early development to postmarketing demand a cultural shift
within the pharmaceutical industry [67]. This shift involves embracing a commitment
to continuous improvement and the flexibility to integrate new knowledge and technol-
ogies. Ensuring that QbD principles are ingrained in organizational practices, from re-
search and development to manufacturing and quality control requires substantial
efforts in education and training [68]. Bridging the gap between theoretical knowledge
174 Neha Jain et al.
https://t.me/med1917
and practical application remains a challenge, requiring concerted efforts to impart
QbD principles as an integral part of pharmaceutical development and manufacturing
processes [69]. The implementation of QbD requires significant resources, including
time, expertise, and equipment. Developing a QbD-based drug product or process can be
expensive and time-consuming. Moreover, the complexity of NDDS can add to the cost,
making it challenging to implement QbD [70]. The development of a QbD-based drug
product also requires extensive testing, which adds to the overall cost. The high cost as-
sociated with the QbD process can be a significant barrier for smaller pharmaceutical
companies and startups, hampering the widespread adoption of QbD in NDDSs [71].
The primary challenge in implementing AI in NDDS is the need for high-quality
and diverse datasets. AI models rely on vast amounts of data for training, and the
availability of comprehensive datasets that accurately represent the complexities of
NPsinteractionswithbiologicalsystemsis crucial. Obtaining such datasets can be
challenging, as the characteri zation of NPs requires advanced analytical techniques,
and the generation of relevant biological data poses its own set of difficulties [72].
Moreover, AI algorithms often function as a black box, in that the reasoning behind
their predictions is not transparent. The ambiguity in AI model interpretation in
NDDS could present a considerable challenge. Comprehending the rationale of how
the AI model arrived at a particular decision can be critical in ensuring the reliability
and safety of the system. Another challenge is that the pharmaceutical industry oper-
ates within a highly regulated environment, and the integration of AI introduces regu-
latory challenges [73]. Ensuring that AI models meet the stringent requirements of
regulatory agencies demands careful validation, standardization, and adherence to es-
tablished guidelines. Navigating these regulatory landscapes, while harnessing the in-
novative potential of AI, remains a significant challenge. The integration of AI with
conventional experimental methodologies poses challenges in terms of harmonizing
disparate datasets and methodologies [74]. Combining the insights derived from ex-
perimental studies with those generated by AI demands a deliberate effort to estab-
lish compatibility and synergy. Bridging the gap between AI-driven approaches and
conventional experimental methods is crucial to ensure the reliability, scientific valid-
ity, and acceptance of advancements in NDDS [74]. The successful implementation of
AI in drug delivery systems requires experts from different fields, including pharma-
ceuticals, chemistry, physics, and computer science. However, the availability of ex-
perts in these fields may be limited, making it challenging to apply AI to NDDS fully.
Moreover, the interdisciplinary nature of this field can present communication bar-
riers, leading to challenges in understanding and implementing the results generated
by AI models [75].
Looking to the future, the convergence of QbD and AI in NDDS presents a land-
scape of promising advancements. QbD principles, based on organized and risk-based
approaches in drug development, are on track to smoothly work together with the
advanced abilities of AI, signifying a major change in how things are done in the phar-
maceutical field [76]. The integration of AI into QbD processes holds tremendous
8 QbD and artificial intelligence in nanoparticulate drug delivery systems 175
https://t.me/med1917
promise, particularly in NDDS. One key aspect is the potential for accelerated and
more cost-effective drug development processes [77]. AI’s ability to analyze extensive
datasets, identify patterns, and optimize processes surpasses conventional methods,
offering a dynamic and efficient approach to formulation design. In the forthcoming
era, the collaboration of QbD and AI is expected to expedite drug development time-
lines and enhance the precision of NDDS [78]. AI’s predictive modeling capabilities
will play a pivotal role in optimizing formulations, predicting CQAs, and streamlining
manufacturing processes. The detailed knowledge of the relationship between CPPs
and CQAs, an essential element of QbD, will be greatly enhanced through AI-driven
insights, ensuring a more comprehensive and efficient approach to quality assurance
[79]. In the future, standardized methodologies for characterizing nanoparticulate sys-
tems will play a pivotal role in advancing QbD and AI integration [80]. Collaborative
efforts within the scientific community to establish reliable analytical techniques and
reference materials are crucial for building a robust foundation. As these methodolo-
gies evolve, they will contribute to the development of a clear roadmap for industry
professionals, aiding in regulatory compliance and ensuring the quality and safety of
NDDS [81]. The evolution of regulatory frameworks to accommodate the unique chal-
lenges posed by these advanced technologies is equally significant. Clear guidelines
and standards will provide regulatory agencies and industry stakeholders with the
key resources for understanding and managing the changing field of NDDS [82].
8.6 Conclusion
In conclusion, the integration of QbD and AI in NDDS represents a transformative syn-
ergy. One of the key benefits of integrating QbD and AI in NDDS is the ability to enhance
precision in formulation design. QbD provides a structured methodology, emphasizing a
thorough understanding of the product and process, and the identification of CQAs.
When coupled with AI, which excels in data analysis and pattern recognition, research-
ers gain a powerful tool to navigate the vast and complex datasets in pharmaceutical
research. AI algorithms can analyze historical data, identify trends, and predict out-
comes, thereby reducing the time traditionally spent on trial-and-error approaches. This
acceleration is particularly significant in the context of NDDS, where the intricacies of
PS, surface properties, and drug release kinetics play a crucial role. QbD, with its empha-
sis on systematic and scientific approaches, provides optimization for drug delivery sys-
tems. AI, on the other hand, contributes by predicting and analyzing the behavior of NPs
in complex biological environments, which includes predicting pharmacokinetics, un-
derstanding drug release kinetics, and optimizing stability. The integration of QbD and
AI facilitates a holistic approach to drug delivery system optimization, ensuring that for-
mulations are not only effective but also tailored to the specific needs of the targeted
patient population. Data quality, interpretability of AI models, and the need for stan-
176 Neha Jain et al.
https://t.me/med1917
dardized regulatory frameworks are areas that require careful consideration. Address-
ing these challenges is pivotal for ensuring the reliability and acceptance of AI-driven
insights in the highly regulated pharmaceutical industry. Looking ahead, the integration
of QbD and AI in NDDS holds profound implications for the future of pharmaceutical
development.
References
[1] Kannadasan, M., Dr., Bichala, P. K., Agrawal, A., & Singh, S. A review: Nano particle drug delivery
system. International Journal of Pharmaceutical Sciences and Medicine, 2020, 5, https://doi.org/10.
47760/ijpsm.2020.v05i12.008.
[2] Ashara, K. C., Paun, J. S., Soniwala, M. M., Chavada, J. R., & Badjatiya, J. K. Nanoparticulate drug
delivery system: A novel approach. International Journal of Drug Regulatory Affairs, 2018, 1,
https://doi.org/10.22270/ijdra.v1i2.109.
[3] Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer,
R. Engineering precision nanoparticles for drug delivery. n.d., https://doi.org/10.1038/s41573-020-
0090-8.
[4] Patel, J., Patel, A., Patel, M., & Vyas, G. Introduction to nanoparticulate drug delivery systems. In:
Pharmacokinetics and Pharmacodynamics of Nanoparticulate Drug Delivery Systems. 2022,
https://doi.org/10.1007/978-3-030-83395-4_1.
[5] Rapalli, V. K., Khosa, A., Singhvi, G., Girdhar, V., Jain, R., & Dubey, S. K. Application of QbD principles
in nanocarrier-based drug delivery systems. In: Pharmaceutical Quality by Design: Principles and
Applications. 2019, https://doi.org/10.1016/B978-0-12-815799-2.00014-9.
[6] Pielenhofer, J., Meiser, S. L., Gogoll, K., Ciciliani, A. M., Denny, M., Klak, M., Lang, B. M., Staubach, P.,
Grabbe, S., Schild, H., Radsak, M. P., Spahn-Langguth, H., & Langguth, P. Quality by design (QbD)
approach for a nanoparticulate imiquimod formulation as an investigational medicinal product.
Pharmaceutics, 2023, 15, https://doi.org/10.3390/pharmaceutics15020514.
[7] Dawoud, M. H. S., Mannaa, I. S., Abdel-Daim, A., & Sweed, N. M. Integrating artificial intelligence
with quality by design in the formulation of Lecithin/Chitosan nanoparticles of a poorly water-
soluble drug. AAPS PharmSciTech, 2023, 24, https://doi.org/10.1208/s12249-023-02609-5.
[8] Vvssn, R., & Reddy M, U. Quality improvement with scientific approaches (QbD, AQbD and PAT) in
generic drug substance development: Review. International Journal of Research and Development
in Pharmacy & Life Science, 2015, 04, https://doi.org/10.4172/2278-0238.1000102.
[9] Alam, M. S., Garg, A., Pottoo, F. H., Saifullah, M. K., Abu-Izneid, T., Manzoor, O., Mohsin, M., & Javed,
M. N. Gum ghatti mediated, one pot green synthesis of optimized gold nanoparticles: Investigation
of process-variables impact using Box-Behnken based statistical design. International Journal of
Biological Macromolecules, 2017, 104, 758–767, https://doi.org/10.1016/J.IJBIOMAC.2017.05.129.
[10] Panda, S. S. Analytical quality-by-design compliant ultrafast liquid chromatographic method for
determination of paliperidone in extended release tablet dosage form. Journal of Bioanalysis and
Biomedicine, 2015, 07, https://doi.org/10.4172/1948-593x.1000133.
[11] Javed, M. N., Alam, M. S., Waziri, A., Pottoo, F. H., Yadav, A. K., Hasnain, M. S., & Almalki, F. A. QbD
Applications for the Development of Nanopharmaceutical Products. In: Pharmaceutical Quality by
Design: Principles and Applications. 2019, https://doi.org/10.1016/B978-0-12-815799-2.00013-7.
[12] Sharma, N., Singh, S., Behl, T., Gupta, N., Gulia, R., & Kanojia, N. Explicating the applications of
quality by design tools in optimization of microparticles and nanotechnology based drug delivery
8 QbD and artificial intelligence in nanoparticulate drug delivery systems 177
https://t.me/med1917
systems. Biointerface Research in Applied Chemistry, 2022, 12, https://doi.org/10.33263/BRIAC124.
43174336.
[13] Simões, A., Veiga, F., Figueiras, A., & Vitorino, C. A practical framework for implementing Quality by
Design to the development of topical drug products: Nanosystem-based dosage forms.
International Journal of Pharmaceutics, 2018, 548, https://doi.org/10.1016/j.ijpharm.2018.06.052.
[14] Vora, L. K., Gholap, A. D., Jetha, K., Thakur, R. R. S., Solanki, H. K., & Chavda, V. P. Artificial
intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics, 2023, 15,
https://doi.org/10.3390/pharmaceutics15071916.
[15] Huynh, L., Neale, C., Pomès, R., & Allen, C. Computational approaches to the rational design of
nanoemulsions, polymeric micelles, and dendrimers for drug delivery. Nanomedicine, 2012, 8,
https://doi.org/10.1016/j.nano.2011.05.006.
[16] Duarte, Y., Márquez-Miranda, V., Miossec, M. J., & González-Nilo, F. Integration of target discovery,
drug discovery and drug delivery: A review on computational strategies. Wiley Interdisciplinary
Reviews: Nanomedicine and Nanobiotechnology, 2019, 11, https://doi.org/10.1002/wnan.1554.
[17] Lou, H., Lian, B., & Hageman, M. J. Applications of machine learning in solid oral dosage form
development. Journal of Pharmaceutical Sciences, 2021, 110, https://doi.org/10.1016/j.xphs.2021.
04.013.
[18] Jiang, J., Ma, X., Ouyang, D., & Williams, R. O. Emerging artificial intelligence (AI) technologies used
in the development of solid dosage forms. Pharmaceutics, 2022, 14, https://doi.org/10.3390/
pharmaceutics14112257.
[19] Egorov, E., Pieters, C., Korach-Rechtman, H., Shklover, J., & Schroeder, A. Robotics, microfluidics,
nanotechnology and AI in the synthesis and evaluation of liposomes and polymeric drug delivery
systems. Drug Delivery and Translational Research, 2021, 11, 345 –352, https://doi.org/10.1007/
S13346-021-00929-2/FIGURES/3.
[20] Alshawwa, S. Z., Kassem, A. A., Farid, R. M., Mostafa, S. K., & Labib, G. S. Nanocarrier drug delivery
systems: characterization, limitations, future perspectives and implementation of artificial
intelligence. Pharmaceutics, 2022, 14, https://doi.org/10.3390/pharmaceutics14040883.
[21] Waheed, A., & Ashwin, K. Assessing the role of artificial intelligence in the design of drug delivery
systems. International Journal of Medical Science and Diagnosis Research, 2020, 4, https://doi.org/
10.32553/ijmsdr.v4i12.725.
[22] Das, K. P., & Chandra, J. Nanoparticles and convergence of artificial intelligence for targeted drug
delivery for cancer therapy: Current progress and challenges. Frontiers in Medical Technology, 2022,
4, https://doi.org/10.3389/fmedt.2022.1067144.
[23] Alshawwa, S. Z., Kassem, A. A., Farid, R. M., Mostafa, S. K., & Labib, G. S. Nanocarrier drug delivery
systems: Characterization, limitations, future perspectives and implementation of artificial
intelligence. Pharmaceutics, 2022, 14, https://doi.org/10.3390/pharmaceutics14040883.
[24] Ori, M. O., Ekpan, F.-D. M., Samuel, H. S., Egwuatu, O. P., Ori, C. M. O., Ekpan, F. M., Samuel, H. S.,
Egwuatu, O. P., & Alnidawi, N. Review article: Integration of artificial intelligence in nanomedicine
A B S T R A C T. Eurasian Journal of Science and Technology Nanomedicine, 2024, 4, 88–104,
https://doi.org/10.48309/EJST.2024.422419.1105.
[25] Serov, N., & Vinogradov, V. Artificial intelligence to bring nanomedicine to life. Advanced Drug
Delivery Reviews, 2022, 184, https://doi.org/10.1016/j.addr.2022.114194.
[26] Ho, D., Wang, P., & Kee, T. Artificial intelligence in nanomedicine. Nanoscale Horizons, 2019, 4,
https://doi.org/10.1039/c8nh00233a.
[27] Sangshetti, J. N., Deshpande, M., Zaheer, Z., Shinde, D. B., & Arote, R. Quality by design approach:
Regulatory need. Arabian Journal of Chemistry, 2017, 10, https://doi.org/10.1016/j.arabjc.2014.01.025.
[28] Bastogne, T., Caputo, F., Prina-Mello, A., Borgos, S., & Barberi-Heyob, M. A state of the art in
analytical quality-by-design and perspectives in characterization of nano-enabled medicinal
178 Neha Jain et al.
https://t.me/med1917
products. Journal of Pharmaceutical and Biomedical Analysis, 2022, 219, https://doi.org/10.1016/j.
jpba.2022.114911.
[29] Mohseni-Motlagh, S. F., Dolatabadi, R., Baniassadi, M., & Baghani, M. Application of the quality by
design concept (QbD) in the development of hydrogel-based drug delivery systems. Polymers
(Basel), 2023, 15, https://doi.org/10.3390/polym15224407.
[30] Fukuda, I. M., Pinto, C. F. F., Moreira, C. D. S., Saviano, A. M., & Lourenço, F. R. Design of
experiments (DoE) applied to pharmaceutical and analytical quality by design (QbD. Brazilian
Journal of Pharmaceutical Sciences, 2018, 54, https://doi.org/10.1590/s2175-97902018000001006.
[31] Prochner, I., & Godin, D. Quality in research through design projects: Recommendations for
evaluation and enhancement. Design Studies, 2022, 78, https://doi.org/10.1016/j.destud.2021.101061.
[32] Walsh, I., Myint, M., Nguyen-Khuong, T., Ho, Y. S., Ng, S. K., & Lakshmanan, M. Harnessing the
potential of machine learning for advancing “Quality by Design” in biomanufacturing. MAbs, 2022,
14, https://doi.org/10.1080/19420862.2021.2013593.
[33] Namjoshi, S., Dabbaghi, M., Roberts, M. S., Grice, J. E., & Mohammed, Y. Quality by design:
Development of the quality target product profile (QTPP) for semisolid topical products.
Pharmaceutics, 2020, 12, https://doi.org/10.3390/pharmaceutics12030287.
[34] Zhang, L., & Mao, S. Application of quality by design in the current drug development. Asian Journal
of Pharmaceutical Sciences, 2017, 12, https://doi.org/10.1016/j.ajps.2016.07.006.
[35] Serov, N., & Vinogradov, V. Artificial intelligence to bring nanomedicine to life. Advanced Drug
Delivery Reviews, 2022, 184, 114194, https://doi.org/10.1016/j.addr.2022.114194.
[36] Khong, J., Wang, P., Gan, T. R. X., Ng, J., Lan Anh, T. T., Blasiak, A., Kee, T., & Ho, D. The role of
artificial intelligence in scaling nanomedicine toward broad clinical impact. In: Nanoparticles for
Biomedical Applications: Fundamental Concepts, Biological Interactions and Clinical Applications.
2019, (pp. 385– 407). Elsevier: https://doi.org/10.1016/B978-0-12-816662-8.00022-9.
[37] Hamilton, S., & Kingston, B. R. Applying artificial intelligence and computational modeling to
nanomedicine. Current Opinion in Biotechnology, 2024, 85, 103043, https://doi.org/10.1016/j.copbio.
2023.103043.
[38] Ho, D., Wang, P., & Kee, T. Artificial intelligence in nanomedicine. Nanoscale Horizons, 2019, 4,
365–377, https://doi.org/10.1039/C8NH00233A.
[39] Shamay, Y., Shah, J., Işık, M., Mizrachi, A., Leibold, J., Tschaharganeh, D. F., Roxbury, D., Budhathoki-
Uprety, J., Nawaly, K., Sugarman, J. L., Baut, E., Neiman, M. R., Dacek, M., Ganesh, K. S., Johnson,
D. C., Sridharan, R., Chu, K. L., Rajasekhar, V. K., Lowe, S. W., Chodera, J. D., & Heller,
D. A. Quantitative self-assembly prediction yields targeted nanomedicines. Nature Materials, 2018,
17, 361–368, https://doi.org/10.1038/s41563-017-0007-z.
[40] Singh, A. V., Ansari, M. H. D., Rosenkranz, D., Maharjan, R. S., Kriegel, F. L., Gandhi, K., Kanase, A.,
Singh, R., Laux, P., & Luch, A. Artificial intelligence and machine learning in computational
nanotoxicology: Unlocking and empowering nanomedicine. Advanced Healthcare Materials, 2020, 9,
https://doi.org/10.1002/adhm.201901862.
[41] Skepu, A., Phakathi, B., Makgoka, M., Mbita, Z., Damane, B. P., Demetriou, D., & Dlamini, Z. AI and
Nanomedicine in Realizing the Goal of Precision Medicine: Tailoring the Best Treatment for
Personalized Cancer Treatment. In: Artificial Intelligence and Precision Oncology. 2023, (pp.181 –
194). Springer Nature Switzerland: Cham, https://doi.org/10.1007/978-3-031-21506-3_9.
[42] Adir, O., Poley, M., Chen, G., Froim, S., Krinsky, N., Shklover, J., Shainsky-Roitman, J., Lammers, T., &
Schroeder, A. Integrating artificial intelligence and nanotechnology for precision cancer medicine.
Advanced Materials, 2020, 32, https://doi.org/10.1002/adma.201901989.
[43] Maojo, V., Fritts, M., De la Iglesia, D., Cachau, R. E., Garcia-Remesal, M., Mitchell, J. A., & Kulikowski,
C. Nanoinformatics: A new area of research in nanomedicine. International Journal of
Nanomedicine, 2012, 7, 3867–3890, https://doi.org/10.2147/IJN.S24582.
8 QbD and artificial intelligence in nanoparticulate drug delivery systems 179
https://t.me/med1917
[44] Yuan, D., He, H., Wu, Y., Fan, J., & Cao, Y. Physiologically based pharmacokinetic modeling of
nanoparticles. Journal of Pharmaceutical Sciences, 2019, 108, 58–72, https://doi.org/10.1016/j.xphs.
2018.10.037.
[45] Singh, A. V., Varma, M., Laux, P., Choudhary, S., Datusalia, A. K., Gupta, N., Luch, A., Gandhi, A.,
Kulkarni, P., & Nath, B. Artificial intelligence and machine learning disciplines with the potential to
improve the nanotoxicology and nanomedicine fields: A comprehensive review. Archives of
Toxicology, 2023, 97, 963–979, https://doi.org/10.1007/s00204-023-03471-x.
[46] Puzyn, T., Rasulev, B., Gajewicz, A., Hu, X., Dasari, T. P., Michalkova, A., Hwang, H.-M., Toropov, A.,
Leszczynska, D., & Leszczynski, J. Using nano-QSAR to predict the cytotoxicity of metal oxide
nanoparticles. Nature Nanotechnology, 2011, 6, 175–178, https://doi.org/10.1038/nnano.2011.10.
[47] Bengio, Y., Delalleau, O., & Simard, C. Decision trees do not generalize to new variations.
Computational Intelligence, 2010, 26, 449–467, https://doi.org/10.1111/j.1467-8640.2010.00366.x.
[48] Mei, H., Zhou, Y., Liang, G., & Li, Z. Support vector machine applied in QSAR modelling. Chinese
Science Bulletin, 2005, 50, 2291–2296, https://doi.org/10.1007/BF03183737.
[49] Saini, B., & Srivastava, S. Nanotoxicity prediction using computational modelling – Review and
future directions. IOP Conference Series: Materials Science and Engineering, 2018, 348, 012005,
https://doi.org/10.1088/1757-899X/348/1/012005.
[50] Tan, P., Chen, X., Zhang, H., Wei, Q., & Luo, K. Artificial intelligence aids in development of
nanomedicines for cancer management. Seminars in Cancer Biology, 2023, 89, 61–75, https://doi.
org/10.1016/j.semcancer.2023.01.005.
[51] Chockaiyan, U., Sitharanjithan, A., Parameswaran, K. L., & Selvaraj, M. Role of Artificial Intelligence in
Cancer Nanotheranostics. In: 2021, 285– 304. https://doi.org/10.1007/978-3-030-76263-6_11.
[52] Dawoud, M. H. S., Mannaa, I. S., Abdel-Daim, A., & Sweed, N. M. Integrating artificial intelligence
with quality by design in the formulation of Lecithin/Chitosan nanoparticles of a poorly water-
soluble drug. AAPS PharmSciTech, 2023, 24, https://doi.org/10.1208/S12249-023-02609-5.
[53] Amasya, G., Aksu, B., Badilli, U., Onay-Besikci, A., & Tarimci, N. QbD guided early pharmaceutical
development study: Production of lipid nanoparticles by high pressure homogenization for skin
cancer treatment. International Journal of Pharmaceutics, 2019, 563, 110–121, https://doi.org/10.
1016/J.IJPHARM.2019.03.056.
[54] Amasya, G., Ozturk, C., Aksu, B., & Tarimci, N. QbD based formulation optimization of semi-solid
lipid nanoparticles as nano-cosmeceuticals. Journal of Drug Delivery Science and Technology, 2021,
66, 102737, https://doi.org/10.1016/J.JDDST.2021.102737.
[55] Dawoud, M. H. S., Fayez, A. M., Mohamed, R. A., & Sweed, N. M. Optimization of nanovesicular
carriers of a poorly soluble drug using factorial design methodology and artificial neural network by
applying quality by design approach. Pharmaceutical Development and Technology, 2021, 26,
1035–1050, https://doi.org/10.1080/10837450.2021.1980009.
[56] Koletti, A. E., Tsarouchi, E., Kapourani, A., Kontogiannopoulos, K. N., Assimopoulou, A. N., &
Barmpalexis, P. Gelatin nanoparticles for NSAID systemic administration: Quality by design and
artificial neural networks implementation. International Journal of Pharmaceutics, 2020, 578,
https://doi.org/10.1016/J.IJPHARM.2020.119118.
[57] Gurba-Bryśkiewicz, L., Maruszak, W., Smuga, D. A., Dubiel, K., & Wieczorek, M. Quality by design
(QbD) and design of experiments (DOE) as a strategy for tuning lipid nanoparticle formulations for
RNA delivery. Biomedicines, 2023, 11, 2752, https://doi.org/10.3390/BIOMEDICINES11102752/S1.
[58] Nguyen, C. N., Tran, B. N., Do, T. T., Nguyen, H., & Nguyen, T. N. D-Optimal optimization and data-
analysis comparison between a DoE software and artificial neural networks of a chitosan coating
process onto PLGA nanoparticles for lung and cervical cancer treatment. Journal of Pharmaceutical
Innovation, 2019, 14, 206–220, https://doi.org/10.1007/S12247-018-9345-X/METRICS.
[59] Maharjan, R., Hada, S., Lee, J. E., Han, H. K., Kim, K. H., Seo, H. J., Foged, C., & Jeong,
S. H. Comparative study of lipid nanoparticle-based mRNA vaccine bioprocess with machine
180 Neha Jain et al.
https://t.me/med1917
learning and combinatorial artificial neural network-design of experiment approach. Int J Pharm,
2023, 640, 123012, https://doi.org/10.1016/J.IJPHARM.2023.123012.
[60] Bao, Z., Yung, F., Hickman, R. J., Aspuru-Guzik, A., Bannigan, P., & Allen, C. Data-driven development
of an oral lipid-based nanoparticle formulation of a hydrophobic drug. Drug Deliv Transl Res, 2023,
https://doi.org/10.1007/s13346-023-01491-9.
[61] Shahsavari, S., Rezaie Shirmard, L., Amini, M., & Dokoosh, F. A. Application of artificial neural
networks in the design and optimization of a nanoparticulate fingolimod delivery system based on
biodegradable poly(3-hydroxybutyrate-Co-3-hydroxyvalerate). Journal of Pharmaceutical Sciences,
2017, 106, https://doi.org/10.1016/j.xphs.2016.07.026.
[62] Basso, J., Mendes, M., Silva, J., Cova, T., Luque-Michel, E., Jorge, A. F., Grijalvo, S., Gonçalves, L., Eritja,
R., Blanco-Prieto, M. J., Almeida, A. J., Pais, A., & Vitorino, C. Sorting hidden patterns in nanoparticle
performance for glioblastoma using machine learning algorithms. International Journal of
Pharmaceutics, 2021, 592, https://doi.org/10.1016/j.ijpharm.2020.120095.
[63] Zagalo, D. M., Silva, B. M. A., Silva, C., Simões, S., & Sousa, J. J. A quality by design (QbD) approach in
pharmaceutical development of lipid-based nanosystems: A systematic review. Journal of Drug
Delivery Science and Technology, 2022, 70, https://doi.org/10.1016/j.jddst.2022.103207.
[64] Dias, A. L., Ferreira, N. N., Ferreira, L. M. B., Pedreiro, L. N., Dos Santos, A. M., & Gremião,
M. P. D. Regulation of Nanotechnology-Based Products Subject to Health Regulations: Application of
Quality by Design (QbD) and Quality Risk Management (QRM). In: 2021, https://doi.org/10.1007/978-
3-030-63389-9_13.
[65] Soni, G., Kale, K., Shetty, S., Gupta, M. K., & Yadav, K. S. Quality by design (QbD) approach in
processing polymeric nanoparticles loading anticancer drugs by high pressure homogenizer.
Heliyon, 2020, 6, https://doi.org/10.1016/j.heliyon.2020.e03846.
[66] Bonaccorso, A., Russo, G., Pappalardo, F., Carbone, C., Puglisi, G., Pignatello, R., & Musumeci,
T. Quality by design tools reducing the gap from bench to bedside for nanomedicine. European
Journal of Pharmaceutics and Biopharmaceutics, 2021, 169, https://doi.org/10.1016/j.ejpb.2021.
10.005.
[67] Zagalo, D. M., Silva, B. M. A., Silva, C., Simões, S., & Sousa, J. J. A quality by design (QbD) approach in
pharmaceutical development of lipid-based nanosystems: A systematic review. Journal of Drug
Delivery Science and Technology, 2022, 70, https://doi.org/10.1016/j.jddst.2022.103207.
[68] Leary, J. F. Quality Assurance and Regulatory Issues of Nanomedicine for the Pharmaceutical
Industry. In: Fundamentals of Nanomedicine. 2022, https://doi.org/10.1017/9781139012898.015.
[69] Drobnjakovic, M., Hart, R., Kulvatunyou, B., Ivezic, N., & Srinivasan, V. Current challenges and recent
advances on the path towards continuous biomanufacturing. Biotechnology Progress, 2023,
https://doi.org/10.1002/btpr.3378.
[70] Wilczy’nski, S., Wilczy’nski, W., Farid Mohseni-Motlagh, S., Dolatabadi, R., Baniassadi, M., & Baghani,
M. Application of the quality by design concept (QbD) in the development of hydrogel-based drug
delivery systems. Polymers, 2023, 15, 4407, https://doi.org/10.3390/POLYM15224407.
[71] Singh, L., & Sharma, V. Quality by design (QbD) approach in pharmaceuticals: Status, challenges and
next steps. Drug Delivery Letters, 2014, 5, https://doi.org/10.2174/2210303104666141112220253.
[72] Kelly, C. J., Karthikesalingam, A., Suleyman, M., Corrado, G., & King, D. Key challenges for delivering
clinical impact with artificial intelligence. BMC Medicine, 2019, 17, https://doi.org/10.1186/s12916-
019-1426-2.
[73] Selvaraj, C., Chandra, I., & Singh, S. K. Artificial intelligence and machine learning approaches for
drug design: Challenges and opportunities for the pharmaceutical industries. Molecular Diversity,
2022, 26, https://doi.org/10.1007/s11030-021-10326-z.
[74] Gupta, P., Kumar, N., Pandey, S., Pandey, R., & Bhatt, G. K. Significance of artificial intelligence in
novel drug delivery system & recent trends. International Journal For Multidisciplinary Research,
2023, 5, https://doi.org/10.36948/ijfmr.2023.v05i02.2493.
8 QbD and artificial intelligence in nanoparticulate drug delivery systems 181
https://t.me/med1917
[75] Gerke, S., Minssen, T., & Cohen, G. Ethical and legal challenges of artificial intelligence-driven
healthcare. In: Artificial Intelligence in Healthcare. 2020, https://doi.org/10.1016/B978-0-12-818438-7.
00012-5.
[76] Sacha, G. M., & Varona, P. Artificial intelligence in nanotechnology. Nanotechnology, 2013, 24,
https://doi.org/10.1088/0957-4484/24/45/452002.
[77] Pokhriyal, P., Chavda, V. P., & Pathak, M. Future prospects and challenges in the implementation of
AI and ML in pharma sector. In: Bioinformatics Tools for Pharmaceutical Drug Product
Development. 2023, https://doi.org/10.1002/9781119865728.ch17.
[78] Hassanzadeh, P., Atyabi, F., & Dinarvand, R. The significance of artificial intelligence in drug delivery
system design. Advanced Drug Delivery Reviews, 2019, 151–152. https://doi.org/10.1016/j.addr.2019.
05.001.
[79] Hickman, R. J., Bannigan, P., Bao, Z., Aspuru-Guzik, A., & Allen, C. Self-driving laboratories: A
paradigm shift in nanomedicine development. Matter, 2023, 6, https://doi.org/10.1016/j.matt.2023.
02.007.
[80] Behgounia, F. Artificial Intelligence Integration with Nanotechnology. Journal of Nanosciences
Research & Reports, 2020, 2, https://doi.org/10.47363/jnsrr/2020(2)117.
[81] Soundarya, R., Halagali, P., Preethi, S., Vikram, H. P. R., Mehdi, S., & Singadi, R. Quality By design
(QBD) approach in processing of nanoparticles loading antifungal drugs. Journal of Coastal Life
Medicine, 2023, 11.
[82] Li, J., Qiao, Y., & Wu, Z. Nanosystem trends in drug delivery using quality-by-design concept. Journal
of Controlled Release, 2017, 256, https://doi.org/10.1016/j.jconrel.2017.04.019.
182 Neha Jain et al.
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана